Dose optimization and target attainment of vancomycin in children

Area of Science:

• Pharmacology
• Pediatric Infectious Diseases
• Clinical Pharmacy

Background:

• Vancomycin, a key antibiotic for gram-positive infections, has been used for over 70 years.
• Optimal dosing and pharmacokinetic/pharmacodynamic (PK/PD) target attainment in pediatric populations remain challenging.
• Current therapeutic drug monitoring (TDM) practices in children require refinement for vancomycin therapy.

Purpose of the Study:

• To review current literature on vancomycin use in pediatric patients.
• To summarize knowledge on optimizing vancomycin dosing for target attainment in special pediatric populations.
• To highlight the benefits of AUC-guided TDM and Bayesian forecasting for vancomycin therapy in children.

Main Methods:

• Literature review of pediatric vancomycin studies.
• Analysis of pharmacokinetic/pharmacodynamic (PK/PD) data in children.
• Evaluation of therapeutic drug monitoring (TDM) strategies, including AUC-guided and trough-only monitoring.
• Assessment of Bayesian forecasting for predicting vancomycin exposure.

Main Results:

• Area under the curve (AUC)-guided TDM is recommended over trough-only TDM for vancomycin in children.
• AUC-guided TDM enhances PK/PD target attainment (AUC0-24h/MIC > 400–600) and reduces acute kidney injury risk.
• Bayesian forecasting improves the accuracy of predicting individual vancomycin concentrations and total exposure in pediatric patients.

Conclusions:

• AUC-guided TDM, ideally incorporating Bayesian forecasting, is suggested for all pediatric age groups and special populations.
• This approach optimizes vancomycin efficacy and safety, ensuring better therapeutic outcomes.
• Further research and clinical implementation of advanced TDM strategies are warranted for pediatric vancomycin therapy.